[Form 4] CYTOKINETICS INC Insider Trading Activity

Cytokinetics, Inc. reported an insider stock transaction by its President & CEO and Director on 12/03/2025.

Rhea-AI Filing Summary

Cytokinetics, Inc. reported an insider stock transaction by its President & CEO and Director on 12/03/2025. The filing shows the disposition of 5,930 shares of common stock at a price of $65.02 per share, recorded under transaction code F.

After this transaction, the reporting person directly beneficially owns 350,202 shares of Cytokinetics common stock. In addition, the filing notes indirect ownership of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.

Insider Trade Summary

Exercise Price or Tax Liability: 5,930 shares

Exercise Price or Tax Liability 3 txns

Insider Blum Robert I

Role President & CEO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	5,930	$65.02	$386K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 350,202 shares (Direct); Common Stock — 2,083 shares (Indirect, by Trust 1); Common Stock — 2,083 shares (Indirect, by Trust 2)

Footnotes (2)

1. F1. Shares held by The Bridget Blum 2003 Irrevocable Trust.
2. F2. Shares held by The Brittany Blum 2003 Irrevocable Trust.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cytokinetics (CYTK) report in this Form 4?

The Form 4 reports that the President & CEO and Director of Cytokinetics, Inc. disposed of 5,930 shares of common stock on 12/03/2025 at a price of $65.02 per share, identified with transaction code F.

How many Cytokinetics (CYTK) shares does the reporting person own after the transaction?

Following the reported transaction, the insider directly beneficially owns 350,202 shares of Cytokinetics common stock.

Does the Cytokinetics (CYTK) insider hold any shares indirectly?

Yes. The filing shows indirect ownership of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.

What is the role of the reporting person at Cytokinetics (CYTK)?

The reporting person is identified as both a Director and an Officer, serving as President & CEO of Cytokinetics, Inc.

Was this Cytokinetics (CYTK) Form 4 filed by more than one reporting person?

No. The Form 4 indicates that it was filed by one reporting person, not jointly with others.

Who signed the Cytokinetics (CYTK) Form 4?

The Form 4 was signed by /s/ John O. Faurescu as attorney-in-fact for Mr. Blum on 12/05/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/05/2025 - 04:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blum Robert I

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/03/2025		F		5,930	D	$65.02	350,202	D
Common Stock								2,083	I	by Trust 1(1)
Common Stock								2,083	I	by Trust 2(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares held by The Bridget Blum 2003 Irrevocable Trust.

2. Shares held by The Brittany Blum 2003 Irrevocable Trust.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Blum	12/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.